Farmavita.Net member is developing innovative concept for glogal branding and distribution of remedies and devices for therapy of arthritis.
Company is looking to joint-venture, collaborative development or in-licensing of non-prescrition products, on exclusive basis.
For more details please contact Farmavita.Net.
Farmavita.Net member has developed technology which enables development of oral dosage forms with controlled and site specific release of active pharmaceutical ingredients. Patent pending application.
Company is looking for following types of cooperation:
- Joint-venture and private equity partners
- Collaborative product development
- Consulting or contract research contracts
WE REQUIRE PLANT PROVEN COMMERCIAL TECHNOLOGY TO MANAUFACTURE SPECTINOMYCIN HCL IN INDIA . TECHNOLOGY LICENCENSORS/MANUFACTURING COMPANIES/CONSULTANTS TO SUBMIT THEIR TECHNICAL AND COMMERCIAL PROFILE AND BUSINESS TERMS.
CONTACT; MR.ARVIND GANDHI -GM MKTG ( API AND FINE CHEMICALS) ASENCE PHARMA PVT.LTD.,MUMBAI.
The gradual spread of software automation in drug development may be getting a boost from open source systems. Most e-clinical systems today--from data capture and storage to trial management and operations--are proprietary, despite the excellent work that solutions providers have done to make their products compatible with existing standards-based and de facto standard industry systems.
Our present communication deals with physicochemical parameters, preliminary phytochemical studies and pharmacological impact of Murdannia nudiflora (L) Brenan as analgesic plant which is used in folklore uses of Assam. No reports are available on standardization parameters hence, the present attempt was undertaken to investigate the standardization parameters to establish its authenticity. The study revealed the presence of wide range of phytoconstituents. The determination of these characters will aid future investigators in their Pharmacological analysis of this species.
1st - 2nd October, 2014, Berlin, Germany
Another year has passed yet budgets and monetary pressures are no less stringent, if anything, they're tighter.
With a more difficult path to launch and increasing competition, how are you going to ensure that every one of your products is approved, gets a fair price and is reimbursed?
Payers' Forum Europe will put you infront of Payers and HTA directors from across Europe as they explain their processes, updates and examples of engagement. You will be engaged in direct, yet open discussion with the most senior European Payers, HTA bodies and Regulators, enabling collaborative conclusions on the specific areas that are causing issues to your business - an advisory board service for the price of a conference ticket.
Seven targeted therapies are available for the treatment of RCC but there is still considerable pipeline activity. Currently approved targeted therapies have been unable to produce durable responses in RCC patients and only delay progression. As a consequence, effective treatment options capable of sustaining responses in RCC are still required.
The leader shows that style is no substitute for substance, that creating an impression is not more potent than acting from one's center.